These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29281604)

  • 21. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.
    Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
    Cardiovasc Drugs Ther; 2016 Jun; 30(3):297-304. PubMed ID: 26936841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
    Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
    Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
    Kereiakes DJ; Robinson JG; Cannon CP; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM
    Am Heart J; 2015 Jun; 169(6):906-915.e13. PubMed ID: 26027630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome　- The ODYSSEY J-IVUS Trial.
    Ako J; Hibi K; Tsujita K; Hiro T; Morino Y; Kozuma K; Shinke T; Otake H; Uno K; Louie MJ; Takagi Y; Miyauchi K
    Circ J; 2019 Sep; 83(10):2025-2033. PubMed ID: 31434809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.
    Qamar A; Giugliano RP; Keech AC; Kuder JF; Murphy SA; Kurtz CE; Wasserman SM; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2019 Jan; 4(1):59-63. PubMed ID: 30540337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
    Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy advantage of evolocumab (AMG 145) dosed at 140mg every 2weeks versus 420mg every 4weeks in patients with hypercholesterolemia: Evidence from a meta-analysis.
    He XX; Zhang R; Zuo PY; Liu YW; Zha XN; Shan SS; Liu CY
    Eur J Intern Med; 2017 Mar; 38():52-60. PubMed ID: 28341307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.
    Koren MJ; Lundqvist P; Bolognese M; Neutel JM; Monsalvo ML; Yang J; Kim JB; Scott R; Wasserman SM; Bays H;
    J Am Coll Cardiol; 2014 Jun; 63(23):2531-2540. PubMed ID: 24691094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J; Berent R
    Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.
    Ballantyne CM; Neutel J; Cropp A; Duggan W; Wang EQ; Plowchalk D; Sweeney K; Kaila N; Vincent J; Bays H
    Am J Cardiol; 2015 May; 115(9):1212-21. PubMed ID: 25784512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases.
    Lankin VZ; Tikhaze AK; Viigimaa M; Chazova IЕ
    Ter Arkh; 2018 Sep; 90(9):27-30. PubMed ID: 30701731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.
    Choi J; Khan AM; Jarmin M; Goldenberg N; Glueck CJ; Wang P
    Lipids Health Dis; 2017 Jul; 16(1):141. PubMed ID: 28738813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
    Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.
    Dias CS; Shaywitz AJ; Wasserman SM; Smith BP; Gao B; Stolman DS; Crispino CP; Smirnakis KV; Emery MG; Colbert A; Gibbs JP; Retter MW; Cooke BP; Uy ST; Matson M; Stein EA
    J Am Coll Cardiol; 2012 Nov; 60(19):1888-98. PubMed ID: 23083772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.